eNauka - pregled

Pregled prema Autor Dixon, Mark

Prikaz rezultata 1 do 2 od 2
GodinaNaslovAutor(i)Tip rezultataMp-kat.
2017Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trialDavies, Andrew; Merli, Francesco; Mihaljevic, Biljana S ; Mercadal, Santiago; Siritanaratkul, Noppadol; Solal-Celigny, Philippe; Boehnke, Axel; Berge, Claude; Genevray, Magali; Zharkov, Artem;
Dixon, Mark; Brewster, Michael; Barrett, Martin; MacDonald, David;
Naučni članak
21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+
2016Longer Term Efficacy and Safety of Subcutaneous Compared with Intravenous Rituximab: Updated Results of the Phase 3 SABRINA StudyDavies, Andrew J; Mihaljevic, Biljana S ; Mercadal, Santiago; Mihaylov, Georgi; Leppa, Sirpa; Cotting, Denise; Veenstra, Klaas; Zharkov, Artem; Dixon, Mark; Barrett, Martin;
Macdonald, David;
Konferencijski rad
Mp kategorija će biti prikazana naknadno.